Original Title: CAR-T Zell-Therapien in Entwicklung, Update 2022

Authors' objectives: CAR-T cell-therapies are commonly indicated as "transformative" therapies referring to the huge expectations associated with them since their market approval in 2017 (USA) and 2018 (Europe). Due to the hopes, but also the enormous prices a horizon scanning (HS) document was first published in 2020 to support budget planning in hospitals. In 2020 13 CAR-T cell-therapies in advanced stages were identified. Of these, in addition to Yescarta® and Kymriah®, that were already approved at that time, three further therapies have since been approved by the European Medicines Agency (EMA) between 8/2020 and 03/2022: Tecartus® (2020), Abcema® (2021) and Breyanzi® (2022). This HS document updates the earlier report by surveying the status of the ten therapies already described in 2020 and is adding additional therapies that have since then reached an advanced phase of clinical testing.

Authors' recommendations: Within the next year (2023), one new CAR-T cell-Therapy for multiple myeloma will eventually be approved, but further development can be expected with the extension of the already approved CAR-T cell-therapies towards earlier lines of therapy and new indications.

Project Status: Completed

URL for project: https://aihta.at/page/homepage/en

Year Published: 2022

URL for published report: http://eprints.aihta.at/1368/1/Policy%20Brief_006a_1st%20Update.pdf

URL for additional information: https://eprints.aihta.at/1368/

English language abstract: An English language summary is available

Publication Type: Rapid Review

Country: Austria

Organisation Name: Austrian Institute for Health Technology Assessment

Contact Address: Garnisongasse 7/20, A-1090 Vienna, Austria

Contact Name: office@aihta.at

Contact Email: office@aihta.at

Copyright: HTA Austria - AIHTA GmbH